Shi, Tingyan
,
Jiang, Rong
Pu, Hong
Yang, Huijuan
Tu, Dongsheng
Dai, Zhiyuan
Cai, Yunlang
Zhang, Yuqin
Cheng, Xi
Jia, Huixun
Tu, Ruiqin
Wang, Huaying
Tang, Jie
Luan, Yuting
Cai, Shumo
Zang, Rongyu http://orcid.org/0000-0002-1334-2398
Article History
Received: 3 April 2019
Revised: 9 July 2019
Accepted: 18 July 2019
First Online: 6 August 2019
Competing interests
: The authors declare no competing interests.
: The trial protocol was compliant with good clinical practice guidelines and the Declaration of Helsinki, and was approved by the ethics committee of Fudan University Cancer Hospital in 18 April 2009 (IRB number: 090371-2). This trial was registered with ClinicalTrials.gov’s number NCT01669226. All patients provided written informed consent before participation.
: The study was supported by funds from the Chinese Anti-Cancer Association (Grant no. HYXH1002), the Zhongshan Development Program (Grant no. 016) and the Shanghai Municipal Health Project (Grant no. 2013ZYJB0201), but the funders had no role in the design, conduct, analysis and interpretation of the data.
: All patients who participated in this trial gave their consents for publication.
: Each original data and Case Report Form for each patient used in the article can be accessed from the ethics committee of each participant hospital.
: This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).